Literature DB >> 15218106

Altered dopamine signaling and MPTP resistance in mice lacking the Parkinson's disease-associated GPR37/parkin-associated endothelin-like receptor.

Daniela Marazziti1, Elisabetta Golini, Silvia Mandillo, Armando Magrelli, Walter Witke, Rafaele Matteoni, Glauco P Tocchini-Valentini.   

Abstract

GPR37 is an orphan G protein-coupled receptor expressed in mammalian brain, and its insoluble aggregates are found in the brain samples of juvenile Parkinson's disease patients. We have produced a Gpr37 knock-out mouse strain and identified several phenotypic features that are similar to those reported for mutants of genes encoding components of synaptic dopamine vesicles. Our results reveal an unanticipated role of GPR37 in regulating substantia nigra-striatum dopaminergic signaling. Gpr37(-/-) mice are viable, with normal brain development and anatomy, but they exhibit reduced striatal dopamine content, enhanced amphetamine sensitivity, and specific deficits in motor behavior paradigms sensitive to nigrostriatal dysfunction. These functional alterations are not associated with any substantial loss of substantia nigra neurons or degeneration of striatal dopaminergic afferences, the main histological marks of Parkinson's disease. The inactivation of GPR37, in fact, has protective effects on substantia nigra neurons, causing resistance to treatment with the Parkinsonian neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15218106      PMCID: PMC454186          DOI: 10.1073/pnas.0403661101

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

1.  High-performance liquid chromatography of biogenic amines and metabolites in brain, cerebrospinal fluid, urine and plasma.

Authors:  R F Seegal; K O Brosch; B Bush
Journal:  J Chromatogr       Date:  1986-04-25

2.  A novel endothelin receptor type-B-like gene enriched in the brain.

Authors:  Z Zeng; K Su; H Kyaw; Y Li
Journal:  Biochem Biophys Res Commun       Date:  1997-04-17       Impact factor: 3.575

3.  Transposon-generated 'knock-out' and 'knock-in' gene-targeting constructs for use in mice.

Authors:  C H Westphal; P Leder
Journal:  Curr Biol       Date:  1997-07-01       Impact factor: 10.834

4.  A cre-transgenic mouse strain for the ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells.

Authors:  F Schwenk; U Baron; K Rajewsky
Journal:  Nucleic Acids Res       Date:  1995-12-25       Impact factor: 16.971

5.  Role of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice.

Authors:  O M Schlüter; F Fornai; M G Alessandrí; S Takamori; M Geppert; R Jahn; T C Südhof
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

6.  Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons.

Authors:  Matthew S Goldberg; Sheila M Fleming; James J Palacino; Carlos Cepeda; Hoa A Lam; Anushree Bhatnagar; Edward G Meloni; Nanping Wu; Larry C Ackerson; Gloria J Klapstein; Mahadevan Gajendiran; Bryan L Roth; Marie-Francoise Chesselet; Nigel T Maidment; Michael S Levine; Jie Shen
Journal:  J Biol Chem       Date:  2003-08-20       Impact factor: 5.157

7.  Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse.

Authors:  Jean-Michel Itier; Pablo Ibanez; Maria Angeles Mena; Nacer Abbas; Charles Cohen-Salmon; Georg Andrees Bohme; Michel Laville; Jeremy Pratt; Olga Corti; Laurent Pradier; Gwenaelle Ret; Chantal Joubert; Magali Periquet; Francisco Araujo; Julia Negroni; Maria Jose Casarejos; Santiago Canals; Rosa Solano; Alba Serrano; Eva Gallego; Marina Sanchez; Patrice Denefle; Jesus Benavides; Gunter Tremp; Thomas A Rooney; Alexis Brice; Justo Garcia de Yebenes
Journal:  Hum Mol Genet       Date:  2003-07-22       Impact factor: 6.150

8.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis.

Authors:  J W Langston; P Ballard; J W Tetrud; I Irwin
Journal:  Science       Date:  1983-02-25       Impact factor: 47.728

9.  Regulation of dopaminergic loss by Fas in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.

Authors:  Shawn Hayley; Stephen J Crocker; Patrice D Smith; Tanaya Shree; Vernice Jackson-Lewis; Serge Przedborski; Matthew Mount; Ruth Slack; Hymie Anisman; David S Park
Journal:  J Neurosci       Date:  2004-02-25       Impact factor: 6.167

10.  Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.

Authors:  Giuseppe Battaglia; Carla L Busceti; Gemma Molinaro; Francesca Biagioni; Marianna Storto; Francesco Fornai; Ferdinando Nicoletti; Valeria Bruno
Journal:  J Neurosci       Date:  2004-01-28       Impact factor: 6.167

View more
  34 in total

1.  GPR37L1 modulates seizure susceptibility: Evidence from mouse studies and analyses of a human GPR37L1 variant.

Authors:  Michelle M Giddens; Jennifer C Wong; Jason P Schroeder; Emily G Farrow; Brilee M Smith; Sharon Owino; Sarah E Soden; Rebecca C Meyer; Carol Saunders; J B LePichon; David Weinshenker; Andrew Escayg; Randy A Hall
Journal:  Neurobiol Dis       Date:  2017-07-06       Impact factor: 5.996

2.  Parkinson's disease-associated receptor GPR37 is an ER chaperone for LRP6.

Authors:  Birgit S Berger; Sergio P Acebron; Jessica Herbst; Stefan Koch; Christof Niehrs
Journal:  EMBO Rep       Date:  2017-03-24       Impact factor: 8.807

3.  Mice lacking Gpr37 exhibit decreased expression of the myelin-associated glycoprotein MAG and increased susceptibility to demyelination.

Authors:  Brilee M Smith; Michelle M Giddens; Jessica Neil; Sharon Owino; TrangKimberly T Nguyen; Duc Duong; Fengqiao Li; Randy A Hall
Journal:  Neuroscience       Date:  2017-06-20       Impact factor: 3.590

4.  mTORC2/rictor signaling disrupts dopamine-dependent behaviors via defects in striatal dopamine neurotransmission.

Authors:  Olga I Dadalko; Michael Siuta; Amanda Poe; Kevin Erreger; Heinrich J G Matthies; Kevin Niswender; Aurelio Galli
Journal:  J Neurosci       Date:  2015-06-10       Impact factor: 6.167

5.  Behavioral effects of dopaminergic agonists in transgenic mice overexpressing human wildtype alpha-synuclein.

Authors:  S M Fleming; J Salcedo; C B Hutson; E Rockenstein; E Masliah; M S Levine; M-F Chesselet
Journal:  Neuroscience       Date:  2006-08-23       Impact factor: 3.590

6.  Liver X receptor β protects dopaminergic neurons in a mouse model of Parkinson disease.

Authors:  Yu-bing Dai; Xin-jie Tan; Wan-fu Wu; Margaret Warner; Jan-Åke Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-23       Impact factor: 11.205

7.  Sulfotransferase 1A3/4 copy number variation is associated with neurodegenerative disease.

Authors:  N J Butcher; M K Horne; G D Mellick; C J Fowler; C L Masters; R F Minchin
Journal:  Pharmacogenomics J       Date:  2017-04-04       Impact factor: 3.550

Review 8.  Behavioral genetic contributions to the study of addiction-related amphetamine effects.

Authors:  Tamara J Phillips; Helen M Kamens; Jeanna M Wheeler
Journal:  Neurosci Biobehav Rev       Date:  2007-11-29       Impact factor: 8.989

9.  GPR37 associates with the dopamine transporter to modulate dopamine uptake and behavioral responses to dopaminergic drugs.

Authors:  Daniela Marazziti; Silvia Mandillo; Chiara Di Pietro; Elisabetta Golini; Rafaele Matteoni; Glauco P Tocchini-Valentini
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-22       Impact factor: 11.205

10.  GPR37 and GPR37L1 are receptors for the neuroprotective and glioprotective factors prosaptide and prosaposin.

Authors:  Rebecca C Meyer; Michelle M Giddens; Stacy A Schaefer; Randy A Hall
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-20       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.